Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC
Adjuvant treatment with alectinib (Alecensa) conferred a significant disease-free survival (DFS) improvement compared with platinum-containing chemotherapy in patients with resected ALK-positive non–small cell lung cancer (NSCLC), according to findings …